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Dear Editor
We read a manuscript entitled ‘Increased serum ferritin levels
in patientswith Crimean-Congo hemorrhagic fever: can it be a new
severity criterion?’ by Barut et al. published in your journal (May
30, 2009). The authors stated that increased serum ferritin levels
may be a useful marker for diagnosis, disease activity, and
prognosis of Crimean-Congo hemorrhagic fever (CCHF), and that
reactive hemophagocytic lymphohistiocytosis (HLH) has been seen
in patients with CCHF. Serum ferritin levels were a diagnostic
marker of HLH and 77.3% of the patients had abnormal serum
ferritin levels. A signiﬁcant negative correlation was observed
between serum ferritin levels and platelet counts.1
The authors suggested that the cause of the increased ferritin
level in patients with CCHF was due to HLH, however they did not
carry out bonemarrow aspirations (BMA), nor did they observe the
erythrocytes, lymphocytes, neutrophils or thrombocytes phagocy-
tosed by macrophages on BMA smear. As mentioned by the
authors, a cytokine storm initiates and triggers the development of
HLH and the serum ferritin level increases as an acute phase
substance.2,3 The pathogenesis of CCHF is complex and various
factors are responsible. The majority of patients have died as a
result of hemorrhage. The causes of hemorrhage are disseminated
intravascular coagulation (DIC), thrombocytopenia, and endothe-
lial damage.1,4 DIC may develop due to direct damage of the
endothelial cells by the virus, immune-mediated liver dysfunction
during the acute phase, and cytokine storm (increase in interleukin
(IL)-1, IL-6, IL-12, IL-18, tumor necrosis factor (TNF)-a, and
interferon (IFN)-g). An inappropriate Th1 response and lack of viral
clearance are the main causes of this cytokine storm.2,3,5
Thrombocytopenia develops in the majority of patients and the
causes of thrombocytopenia are DIC and HLH.
We believe that high serum lactate dehydrogenase (LDH) levels
and soluble CD25 levels, or decreased natural killer (NK) cell
activity, which are indicative of macrophage activation syndrome
andHLH, are early indicators of CCHF as good as high serum ferritin
levels. In addition, thrombocytopenia and increased serum D-
dimer are early ﬁndings of DIC6. We think that when a patient with1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.08.011CCHF has thrombocytopenia and an increase in serum D-dimer,
DIC has developed. The patient then receives fresh frozen plasma
for factor replacement and corticosteroid therapy, such as mega-
dose methylprednisolone (20–30 mg/kg/day p.o. or i.v., before 6
a.m.), for inhibiting the cytokine storm, stabilization of the cell
membrane, and vascular endothelial integrity. Ribavirin treatment
is controversial in the hemorrhagic period; it has been found to be
effective in the early stage of the disease.7
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